Skip to main content
YUNGJIN PHARM. CO., LTD logo

YUNGJIN PHARM. CO., LTD — Investor Relations & Filings

Ticker · 003520 ISIN · KR7003520004 KO Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2019-11-29 Audit Report / Informat…
Country KR South Korea
Listing KO 003520

About YUNGJIN PHARM. CO., LTD

https://eng.yungjin.co.kr/

Yungjin Pharm. Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products for domestic and international markets. The company's portfolio includes a range of prescription drugs, with a focus on areas such as cephalosporin antibiotics and antipsychotic medications. Yungjin Pharm is actively involved in advancing its R&D pipeline, which includes collaborative research for treatments of rare conditions like mitochondrial diseases. Leveraging extensive drug production expertise and R&D capabilities, the company operates as a key affiliate within the KT&G Group's bio/pharmaceutical business.

Recent filings

Filing Released Lang Actions
대규모기업집단현황공시[분기별공시(개별회사용)]
Audit Report / Information Classification · 95% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by Youngjin Pharm, a subsidiary of the KT&G business group. It contains detailed tables regarding share ownership, inter-company transactions, debt guarantees, and collateral, which are standard regulatory disclosures required by the Korea Fair Trade Commission. Since this is a formal regulatory filing that does not fit into specific categories like 10-K, IR, or ER, it is classified as a Regulatory Filing (RNS). Q2 2024
2019-11-29 Korean
[첨부추가]분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '영진약품(주)' (Yungjin Pharm. Co., Ltd.) covering the period from January 1, 2019, to September 30, 2019. It contains detailed financial statements, management discussion and analysis, and business operations information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) from Youngjin Pharm, detailing quarterly financial performance (revenue, operating profit, net income) for 2019.3Q. It provides key financial highlights and is explicitly labeled as provisional data (잠정치) intended for investors and analysts. This fits the definition of an Earnings Release (ER), which focuses on the initial announcement of periodic financial results. Q3 2019
2019-11-06 Korean
기업설명회(IR)개최(안내공시)
Regulatory Filings Classification · 95% confidence The document is a short announcement (812 characters) regarding the scheduling and logistics of an upcoming Investor Relations (IR) meeting. It provides the date, time, location, and purpose of the meeting, and directs readers to the company website for the actual presentation materials. Per the 'Menu vs Meal' rule, this is an announcement of an event/report rather than the report itself, and it fits the definition of a Regulatory Filing (RNS) as it is a standard corporate disclosure of an event.
2019-11-06 Korean
불성실공시법인미지정
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from the Korea Exchange (KRX) regarding the status of a company (Youngjin Pharm) as a 'non-designated' entity for unfair disclosure. It details the regulatory decision, the reason for the decision (mitigation of penalty points), and references the relevant disclosure regulations. Since this is a specific regulatory notice regarding disclosure compliance and does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2019-10-18 Korean
소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a lawsuit ('소송등의제기ㆍ신청') filed against the company (Youngjin Pharm). It details the plaintiff, the claim amount, the court, and the company's planned legal response. This fits the definition of a Legal Proceedings Report (LTR) as it concerns significant litigation involving the company.
2019-10-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.